Cardiac Effects of Leukemia
Leukemia affects the heart through both direct disease-related mechanisms and treatment-related cardiotoxicity, with the latter representing the predominant and most clinically significant threat to morbidity and mortality.
Disease-Related Cardiac Effects
Acute leukemia itself causes measurable cardiac dysfunction even before chemotherapy initiation. Patients with acute leukemia demonstrate higher left ventricular mass, increased LV volumes, and reduced global longitudinal strain (GLS) compared to matched controls without cancer (GLS: -19.3 ± 2.7% vs -20.9 ± 1.9%, p < 0.001) 1. These alterations occur despite preserved ejection fraction and likely result from high cytokine release or direct leukemic myocardial infiltration 1, 2.
Among patients with acute leukemia before chemotherapy, independent risk factors for impaired GLS include:
- High body mass index
- Low baseline LVEF
- Low circulating lymphocyte count 1
This pre-existing cardiac dysfunction is clinically important because it predicts subsequent heart failure risk. Baseline GLS >-15% (indicating greater impairment) carries 6 points in validated heart failure risk scoring and independently predicts all-cause mortality (HR: 1.73; 95% CI: 1.30-2.31; p < 0.001) 3.
Treatment-Related Cardiac Complications
Anthracycline Cardiotoxicity
Heart failure from cancer therapy carries a 3.5-fold increased mortality risk compared with idiopathic cardiomyopathy 4. Anthracyclines represent the most significant cardiotoxic threat in leukemia treatment, with dose-dependent toxicity that manifests both acutely and years after exposure.
Symptomatic heart failure occurs in 8.9% of acute leukemia patients treated with anthracyclines 3. The cumulative incidence after 30 years reaches approximately 8% in patients receiving ≥250 mg/m² 4. Risk increases exponentially with dose:
- <400 mg/m²: 11% subclinical dysfunction
- 400-599 mg/m²: 23%
- 600-799 mg/m²: 47%
- ≥800 mg/m²: 100% 4
Compared to survivors receiving 1-150 mg/m² of anthracyclines, those receiving higher doses have mean relative risks of decreased systolic function (LV fractional shortening <30%) of:
- 151-300 mg/m²: RR 7.0 (95% CI: 1.5-10.0)
- 301-450 mg/m²: RR 7.8 (95% CI: 2.8-21.3)
450 mg/m²: RR 10.6 (95% CI: 3.3-33.4) 4
Even low cumulative anthracycline doses (<250 mg/m²) cause subclinical cardiac abnormalities in 30% of patients at median 13.3 years post-treatment 5. Male survivors show significantly reduced left ventricular shortening fraction, with 16% (3 of 19) having SF below 30% 5.
Tyrosine Kinase Inhibitor Cardiotoxicity
Chronic lymphocytic leukemia patients treated with covalent BTK inhibitors experience substantial cardiovascular burden. The most common incident cardiovascular adverse events include:
- Hypertension: 23.4%
- Atrial fibrillation: 10.2%
- Ventricular arrhythmias: 10.1%
- Heart failure: 8.5%
- Atrial flutter: 4.2% 6
Ibrutinib carries the highest atrial fibrillation risk among leukemia therapies, with annualized incidence rates of 19.9-80.8 cases per 1000 patient-years 7. Acalabrutinib demonstrates 2-3 fold lower incidence rates for hypertension, atrial fibrillation, and atrial flutter compared to ibrutinib, with Kaplan-Meier estimates showing 83% vs 72% likelihood of remaining CVAE-free at 12 months 6.
Patients experiencing cardiovascular adverse events have significantly worse overall survival and higher rates of treatment switching 6.
Dasatinib causes pulmonary arterial hypertension in 0.45-5% of chronic myeloid leukemia patients, which can occur after more than 1 year of treatment 8. The mechanism involves inhibition of SRC kinase regulating smooth muscle proliferation and vasoconstriction 8. Pleural effusion occurs in 28-33% of patients, with risk factors including prior cardiac history, hypertension, twice-daily dosing, and advanced age 8.
Monoclonal Antibody Cardiotoxicity
Trastuzumab-induced cardiac dysfunction occurs primarily during treatment through inhibition of the cardiomyocyte HER2 receptor 4. When combined with anthracyclines, the incidence of adverse cardiac effects increases sharply to 27% in patients with baseline LVEF <54% 9. Unlike anthracycline toxicity, trastuzumab-induced dysfunction appears reversible after treatment cessation without persistent morphological changes 4.
Risk Stratification and Prevention
A validated 21-point heart failure risk score for acute leukemia patients includes:
- Baseline GLS >-15%: 6 points
- Baseline LVEF <50%: 4 points
- Pre-existing cardiovascular disease: 4 points
- Acute myeloid leukemia (vs ALL): 4 points
- Cumulative anthracycline dose ≥250 mg/m²: 2 points
- Age >60 years: 1 point 3
Risk stratification yields:
- Low risk (0-6 points): 1.0% one-year HF incidence
- Moderate risk (7-13 points): 13.6%
- High risk (14-21 points): 35.0% 3
Cardioprotective Strategies
Carvedilol and nebivolol demonstrate cardioprotective effects when initiated with anthracycline therapy, resulting in higher LVEF preservation 4. Carvedilol's antioxidant properties and iron-chelating ability prevent cardiac histopathology and strain abnormalities 4. Propranolol may be cardiotoxic and metoprolol shows neutral effect 4.
ACE inhibitors preserve mitochondrial function and attenuate fibrosis when initiated one week prior to doxorubicin 4. Enalapril using troponin I elevation for risk stratification prevents cardiotoxicity in high-risk anthracycline patients 4.
Monitoring Requirements
Baseline comprehensive cardiovascular evaluation is mandatory before initiating cardiotoxic chemotherapy 9. This includes:
- Echocardiogram with LVEF measurement for all patients receiving anthracyclines, especially with CV risk factors, age >60 years, previous CVD, or prior mediastinal irradiation 9
- Baseline troponin I and BNP measurement 9
- Assessment of cardiac structure, performance, and hemodynamics 9
Serial monitoring during treatment includes:
- LVEF measurements at baseline, 3,6,9,12, and 18 months 9
- Cardiac biomarkers at baseline and periodically 9
- Global longitudinal strain assessment, with 10-15% early reduction being most useful for predicting cardiotoxicity 4
For dasatinib-treated patients, surveillance includes:
- NYHA/WHO functional class assessment every 3 months
- Echocardiographic pulmonary arterial pressure every 3 months
- Right heart catheterization for suspected PAH 8
Absolute and Relative Contraindications
Severe left ventricular dysfunction (LVEF <40%), decompensated heart failure, recent myocardial infarction, unstable angina, and uncontrolled arrhythmias require stabilization before initiating cardiotoxic agents 9. Prior anthracycline exposure approaching cumulative dose limits (doxorubicin 500-550 mg/m²) is associated with 4-36% cardiotoxicity incidence 9.
Management algorithm based on baseline LVEF:
- LVEF ≥54%: Standard monitoring
- LVEF 40-53%: Consider alternative regimens or cardioprotective strategies
- LVEF <40%: Defer cardiotoxic chemotherapy 9